BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

Ella Day | June 6, 2025 | News story | Research and Development |  BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership 

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types.

BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small cell lung cancer, and a further investigation in triple-negative breast cancer is expected to begin later this year.

The companies will jointly lead a comprehensive development programme, including monotherapy and combination strategies. More than 20 trials are ongoing or planned, with over 1,000 patients treated to date.

Advertisement

“We believe BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumour indications,” said Ugur Sahin, chief executive officer of BioNTech. “Our collaboration with BMS, aims to accelerate BNT327’s development to fully realise its potential.”

Christopher Boerner, chief executive officer of BMS, added: “We are impressed by the innovation that BioNTech has achieved to date, and we look forward to partnering to accelerate existing clinical trials and time to market, while expanding the number of potential indications.”

Ella Day

6/6/25

Related Content

Highlighting the value of lab research for healthcare innovation

Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory …

Charity commits £800,000 to AI research into late breast cancer recurrence

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

Most advanced breast cancer patients treated in community settings, Phesi study finds

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

The Gateway to Local Adoption Series

Latest content